Echo Phenotypes Boost PAH Risk Prediction 02/07/26
Welcome to Cardiology Today â Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.
Article Links:
Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. (Journal of the American College of Cardiology)
Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. (European heart journal)
Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry. (JACC. Heart failure)
Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults. (JAMA cardiology)
Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/
đ Featured Articles
Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41653174
Summary: The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.
Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41649944
Summary: This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.
Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41653179
Summary: V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.
Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41637062
Summary: S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.
Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41636023
Summary: C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications.
đ Transcript
Today’s date is February 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.
Article number two. Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.
Article number three. Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 L. V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.
Article number four. Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in U. S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.
Article number five. Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-H. C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
cost-effectiveness, HeartMate 3, left ventricular assist device, cavotricuspid isthmus ablation, semaglutide, atrial fibrillation, cardiac registry, pulmonary arterial hypertension, cardiovascular disease prevention, prognosis, young patients, echocardiography, major adverse cardiovascular events, right ventricular remodeling, radiofrequency ablation, risk stratification, diabetes, pulsed field ablation, mitral regurgitation, advanced heart failure, H. C. M. subtypes, hypertrophic cardiomyopathy, atrial flutter, heart transplantation.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow